| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7129232 | CUBIST PHARMS LLC | Cephem compounds |
May, 2028
(4 years from now) | |
| US8685957 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(8 years from now) | |
| US8476425 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(8 years from now) | |
| US8906898 | CUBIST PHARMS LLC | Solid forms of ceftolozane |
May, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028963 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(8 years from now) | |
| US9724353 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(8 years from now) | |
| US11278622 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(9 years from now) | |
| US10420841 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(9 years from now) | |
| US8968753 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(9 years from now) | |
| US9872906 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(9 years from now) | |
| US9320740 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(9 years from now) | |
| US10376496 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(10 years from now) | |
| US10933053 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(10 years from now) | |
| US10125149 | CUBIST PHARMS LLC | Synthesis of cephalosporin compounds |
Aug, 2035
(11 years from now) | |
Zerbaxa is owned by Cubist Pharms Llc.
Zerbaxa contains Ceftolozane Sulfate; Tazobactam Sodium.
Zerbaxa has a total of 14 drug patents out of which 0 drug patents have expired.
Zerbaxa was authorised for market use on 19 December, 2014.
Zerbaxa is available in powder;intravenous dosage forms.
Zerbaxa can be used as treatment of ventilator-associated bacterial pneumonia (vabp), treatment of ventilator-associated bacterial pneumonia, treatment of hospital-acquired bacterial pneumonia, methods of treating bacterial illnesses, treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis, treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis, complicated intra-abdominal infections (ciai), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years of age).
Drug patent challenges can be filed against Zerbaxa from 20 December, 2023.
The generics of Zerbaxa are possible to be released after 14 August, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Patient Population(NPP) | Apr 21, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hospital-acquired bacterial pneumonia; Treatment of ventilator-associated bacterial pneumonia; Treatment of ventilator-associated bacterial pneumonia (vabp); Complicated intra-abdominal i...
Dosage: POWDER;INTRAVENOUS
ZERBAXA family patents
